Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

• Published in: Cancer pathogenesis and therapy Vol. 2; no. 4; pp. 268 - 275
• Main Authors: Zhang, Changgong, Chen, Jianhua, Wu, Huijuan, Wang, Jun, Gao, Liying, Zhao, Jun, Sun, Yan, Jia, Zhongyao, Mu, Xinlin, Bai, Chunmei, Wang, Rui, Wu, Kailiang, Liu, Qiang, Shi, Yuankai
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2024; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China%Department I of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410083, China%Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China%Department II of Head and Neck Tumor, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050, China%Department III of Radiotherapy, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050, China%Department I of Thoracic Oncology, Beijing Cancer Hospital, Beijing 100142, China%Department of Oncology, Linyi People's Hospital, Linyi, Shandong 276002, China%Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100032, China%Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China%Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China%Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200030, China%Department I of Oncology, Shenyang Chest Hospital, Shenyang, Liaoning 110044, China; Elsevier
• Subjects: Anlotinib; Efficacy; Penpulimab; Phase II trial; Safety; Small cell lung cancer; Efficacy; Anlotinib; Small cell lung cancer; Penpulimab; Safety; Phase II trial

Currently, the need for new therapeutic strategies involving programmed cell death protein-1 (PD-1) monoclonal antibodies in the second-line setting of small cell lung cancer (SCLC) is urgent. This study aimed to evaluate the efficacy and safety of anlotinib plus penpulimab as a second-line treatmen...